marketing chemeq, page-2

As far as the Human side is concerned, PHASE III will normally be either shared or a Pharma Partner will pay for it and pay royalties later.

It is a bit early to talk about this but if the product is successful and in demand, some high milestone payments may be made by the Partner.

What bugs me that in most posts reference is made to animals only and the share price based on that.

I on the other hand am concentrating even more so on the human side potential.

Gerry